The Oncology Shot with Timothee Olivier
Timothée Olivier, Sahar van Waalwijk, Christopher Rios, Marco Donia, Yago GaritaonaindiaMy Personal Substack
| Platform |  | Pricing | Only free issues | Publishes | Twice weekly |
|---|---|---|---|---|---|
| Issues | 35 | Founded | a year ago | Last Issue | 11 days ago |
| Active | |||||
Read this Newsletter
theoncologyshot.comLatest Issues
Daraxonrasib Is FDA-Approved: Both Good News and Bad News
Daraxonrasib is an oral RAS(ON) multi-selective, non-covalent inhibitor. In RASolute 302, the product was tested in the second-line setting of patients with metastatic pancreatic cancer, with a median survival gain from 6.7 to 13.2 months....
Beyond Cross-Trial Comparisons: What Digitized Survival Curves Can Really Tell Us
In today’s guest post, it’s my great pleasure to welcome Yago Garitaonaindia and Marco Donia. The power of reconstructed datasets from published curves cannot be overstated. In a series of three peer-reviewed 2026 publications, they demonst...
Sham Controls and Tumor Treating Fields: Does the Ethical Argument Hold?
Today, we are covering our new work just published in The European Journal of Cancer, entitled “Tumor treating fields: Will the evidence gap ever be filled?”. We thank our co-authors Sruthi Ranganathan, , and Alessandro Hammond!
##...
EMA and FDA Advocate Removing Amgen’s Drug from the Market: How Unblinded Personnel Manipulated the ADVOCATE Trial
It’s my pleasure to welcome back Sahar Van Waalwijk, who covers an important topic following an unusual development. Enjoy! Timothée
Imagine a wine competition. Judges taste wines from unlabelled bottles and score them without knowi...
Additional Insights Into Early Daraxonrasib Data
Daraxonrasib is making headlines. A few weeks ago, a press release reported positive phase 3 results from the RASolute 302 trial in second-line metastatic pancreatic cancer, with particular emphasis on a secondary endpoint: overall survival...
Audience Metrics
Subscribers, engagement, traffic and sponsorship for The Oncology Shot with Timothee Olivier.
| Subscribers | Engagement | 72 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Chart Rankings
How this newsletter ranks in the official Substack charts.
| #141 |
Authors
The writers behind this newsletter.
Swiss oncologist at Geneva University Hospital. Research on trial methodology, health policy, and critical appraisal. I joined Vinay Prasad’s research lab in November 2021. Geneva Ethics Committee. Co-EiC ESMO Rare Cancers. No COI. Views mine.
Pharmacist Medicine & Society (PharmD-PhD), National Funder’s Committee for Evaluation of Specialised Medicines and Companion Diagnostics, CZ. Associate Professor of Medical Oncology, focused on Access to Medicines, LUMC, NL
UCSF medical student, Harvard alum. Before med school, I worked in gene-editing research and industry-academic collaborations. Now focused on high-value care and healthcare policy. How do we pay for increasingly expensive therapies and innovations?
Clinician-Scientist, Oncologist, Professor of Immuno-Oncology National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
Medical Oncologist and Translational Researcher, National Center for Cancer Immune Therapy, CCIT-DK, Copenhagen University Hospital, DK.
Frequently Asked Questions
How can I access the email archive for The Oncology Shot with Timothee Olivier?
You can find recent issues that have been published by The Oncology Shot with Timothee Olivier on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does The Oncology Shot with Timothee Olivier have?
To see how many people subscribe to The Oncology Shot with Timothee Olivier, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in The Oncology Shot with Timothee Olivier?
Newsletter advertising can be extremely effective when it's done right. Before you pitch The Oncology Shot with Timothee Olivier as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like The Oncology Shot with Timothee Olivier?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The Oncology Shot with Timothee Olivier using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to The Oncology Shot with Timothee Olivier?
Scroll up to where it says Related Newsletters to see other publications like The Oncology Shot with Timothee Olivier. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact The Oncology Shot with Timothee Olivier?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.